Sugi Predict

Sugi Predict / Compounds / SCHEMBL22990239

SCHEMBL22990239

SCHEMBL22990239

C[C@@H]1[C@H](O)CC(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ USP2 O75604 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RECQL P46063 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ NR1H2 P55055 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26198255 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL18593025 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL29222219 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL23186706 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL19420020 0.86 CHRM2 (0.46) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL22096750 0.86 CHRM2 (0.46) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL31750113 0.81 CHRM2 (0.39) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL3738817 0.81 CHRM2 (0.39) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL20406585 0.80 CHRM2 (0.43) CHRM2CHRM1CHRM3USP2SMN1; SMN2
SCHEMBL483259 0.80 CHRM2 (0.43) CHRM2CHRM1CHRM3USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094675-A Deuterated organic compounds and use thereof — 2026-05-26 — — CN disclosed
CN-122094936-A Deuterated organic compounds and use thereof — 2026-05-26 — — CN disclosed
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-05-07 — — US disclosed
EP-4734983-A2 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF Engrail Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
US-12606572-B2 Substituted heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2026-04-21 — — US disclosed
EP-4724445-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF Kumquat Biosciences Inc. (US) 2026-04-15 — — EP disclosed
US-20260098011-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF ENGRAIL THERAPEUTICS INC (US) 2026-04-09 — — US disclosed
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-02-12 — — US disclosed
US-20260028357-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-01-29 — — US disclosed
US-12528818-B2 Compositions and methods for inhibition of RAS LEIDOS BIOMEDICAL RESEARCH, INC. (US) 2026-01-20 — — US disclosed
EP-4373822-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Theras Inc. (US) 2024-05-29 — — EP disclosed
CN-117916238-A Compositions and methods for inhibiting RAS 瑟拉斯有限公司 2024-04-19 — — CN disclosed
WO-2023130117-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF ENGRAIL THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
WO-2023130117-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF ENGRAIL THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
WO-2023004102-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS THERAS, INC. (US) 2023-01-26 — — WO disclosed
WO-2023004102-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS THERAS, INC. (US) 2023-01-26 — — WO disclosed
US-20220289732-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2022-09-15 — — US disclosed
EP-4010334-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS Novartis AG (CH) 2022-06-15 — — EP disclosed
WO-2021028806-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 — — WO disclosed
WO-2021026672-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606572-B2 Substituted heterocycles and uses thereof KRAS, HRAS, MYC CHRM2 3813/4885CHRM1 4253/4885CHRM3 2721/4885
US-20260098011-A1 DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF SLC6A3, DRD2, SLC6A2 CHRM2 187/4885CHRM1 389/4885CHRM3 539/4885
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS CHRM2 4224/4885CHRM1 4229/4885CHRM3 4767/4885
US-20220289732-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS WDR5, WDR77, WDR1 CHRM2 4874/4885CHRM1 4865/4885CHRM3 4862/4885
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS CHRM2 3607/4885CHRM1 3079/4885CHRM3 4024/4885
US-12528818-B2 Compositions and methods for inhibition of RAS KRAS, NRAS, HRAS CHRM2 3912/4885CHRM1 3585/4885CHRM3 4676/4885
US-20260028357-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF KRAS, HRAS, MYC CHRM2 3813/4885CHRM1 4253/4885CHRM3 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.